ArticleWorld journal of urology2025
The effect of lymph node dissection on oncological outcomes in contemporary robotic salvage radical prostatectomy patients: a junior ERUS/YAU collaborative study.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSurgical features associated with better cancer-control outcomes are under investigation for salvage radical prostatectomy patients undergoing robotic approaches.
methodsThe Junior ERUS/Young Academic Urologist Working Group in Robotics in Urology conducted a multicentric project to investigate the effect of lymph node dissection (LND) and pN stage on biochemical recurrence-free (BCR), metastases-free (MFS) and overall survival (OS) outcomes in 444 robotic salvage radical prostatectomy (s-RARP) patients.
resultsOf all patients, 63% underwent LND with a median of eight removed lymph nodes. Patients without LND more frequently underwent initial focal therapy (60% vs. 37%) and harbored higher pathological Gleason score 8-10 (both p ≤ 0.02). In BCR analyses, no differences were observed between patients with vs. without LND with 24-months BCR-free survival rates of 74.8% vs. 73.6%. In OS analyses, better OS for LND patients (HR: 0,39, p = 0.049) was observed with 60-months OS rates of 81.3% vs. 92.1% for no LND vs. LND. Of LND patients. 16% harbored pN1 stage, which was associated with worse BCR-free survival (HR: 2.0,p = 0.025) with 60-months BCR-free survival rates of 63% for pN0 vs. 49.6% for pN1. In MFS analyses, no difference between both groups were observed. In OS analyses, the observed differences did not reach statistical significance with 60-months OS rates of 93.4% for pN0 vs. 84.7% for pN1.
conclusionRates of LND are relatively low in contemporary s-RARP patients and are more frequently performed in patients with worse characteristics. However, LND may be associated with better OS, while pN1 patients are associated with worse cancer-control outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.